AstraZeneca

Open: 63.86 Close: 63.96 Change: 0.1

14 things an AI found about AstraZeneca that you should know before investing.

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, Astra, drug, company, Zeneca, Cellectis, UK, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

AstraZeneca PLC ADR AZN, -0.34% dropped 0.34%, down 0.38% to $63.96 Friday. Company rejected a final offer from Pfizer of £55 per share, valued the company at £69.4   billion. Company to invest $245 million in French biotechnology company.

Today's News

AstraZeneca PLC ADR AZN, -0.34% dropped 0.34%, down 0.38% to $63.96 Friday, on what proved to be an all-around favorable trading session for the stock market. AstraZeneca has announced that its hyperkalaemia drug, Lokelma doubled the odds of maintaining lifesaving therapy in patients living with heart failure or kidney disease. GlobalDatas Pharmaceutical Intelligence Centre forecasts the total worldwide sales of the drug at around $799m. AstraZeneca announced plans for a major corporate restructuring in March 2013. The company rejected a final offer from Pfizer of £55 per share, valued the company at £69.4   billion. AstraZeneca has its corporate headquarters in Cambridge, United Kingdom, and its main research and development (R&D) centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) AstraZecas drug tremelimumab was approved as an orphan drug for the treatment of mesothelioma. Company has recovered fourx293 NATMAX Graveyard � tender ComeyStrangeoppable ic watch AstraZeneca agreed to pay £505 million to settle a UK tax dispute related to transfer mispricing. In 2010, AstraZecas paid £505 million to settle tax dispute relating to transfer mispricing in UK. In August 2020 Astra Zeneca declared towards European Commission and EU member states: 13.1 AstraZeneca underwrites Cambridge-Sweden flights. AstraZeneca wins approval for Ovarian-Cancer Drug It Had Dropped. Valeant Licenses Brodalumab from Astra Zeneca for $445M AstraZeneca to pay $520 million for Off-label Drug Marketing U.S. Pharmaceutical giant Astra Zeneca agrees to pay £505m to settle UK tax dispute. Company to invest $245 million in French biotechnology company Cellectis. AstraZeneca has partnered with Axis Communications to develop a surveillance solution for its Gaithersburg R&D campus. “We know innovation is at the forefront for Astra Zeneca, and its employees are dedicated to making strides for the biopharmaceutical industry. A supply shortage means a drug that can prevent respiratory syncytial virus (RSV) in infants wont have a major immediate impact, childrens hospitals said. Childrens hospitals are preparing for a surge in admissions this respiratory disease season. AstraZeneca continues to advance its ambition in cell therapy for oncology and autoimmune diseases as well as in genomic medicine. AstraZeneca plc has fallen 3.14% over the past month, closing at $67.42 on October 6. Astrazeneca has a Long-Term Technical rank of 58. AstraZeneca Cellectis will receive an initial payment of $105m from Astra Zeneca in Q4 2023, which comprises a $25m upfront cash payment under the terms of a research collaboration agreement and an $80m equity investment. Post-closing of this second investment, Astra will hold a total equity stake of c.c. AstraZeneca is best known for its contributions in the field of pharmaceuticals, particularly in oncology, respiratory diseases, cardiovascular health, and immunology. AstraZeneca to invest $245 million in adeal with biotechnology company Cellectis to develop next-generation therapeutics in oncology, immunology and rarediseases. Cellectiss stock skyrocketed and was up by over 174% in pre-market trading. AstraZeneca has agreed to make an initial equity investment of $80M in Cellectis by subscribing for 16,000,000 ordinary shares, at a price of $5.00 per share. Astra has an option for a worldwide exclusive license on the candidate products. AstraZeneca said on Wednesday it would invest $245 million in French biotechnology company Cellectis in a deal aimed at speeding up the development of therapeutics in areas including oncology, immunology and rare diseases. JMP sees AZN deal as ‘great option for Cellects to close financing overhang.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, Astra, drug, company, Zeneca, Cellectis, UK, and the most common words in the summary are: astrazeneca, news, company, trial, her2, drug, cellectis, . One of the sentences in the summary was: Company to invest $245 million in French biotechnology company.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #news #company #trial #her2 #drug #cellectis.